Cytokinetics Earnings Outlook

Cytokinetics (NASDAQ: CYTK) announces its next round of earnings Thursday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.

Earnings and Revenue

Sell-side analysts are expecting Cytokinetics's loss per share to be near 70 cents on sales of $6.32 million.

In the same quarter last year, Cytokinetics reported earnings per share of 16 cents per share on revenue of $33.1 million. If the company were to match the consensus estimate when it reports Thursday, EPS would have fallen 537.5 percent. Sales would be down 80.93 percent on a year-over-year basis.

Here's how the Cytokinetics's reported EPS has stacked up against analyst estimates in the past:

Stock Performance

Over the last 52-week period, shares are down 23.13 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.

Analyst estimates are adjusted lower for EPS and revenues over the past 90 days. The popular rating by analysts on Cytokinetics stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

Cytokinetics' Q4 conference call is scheduled to begin at 4:00 p.m. ET and can be accessed here: https://cytokinetics.com/